Brief: Chemocentryx Reports Safety Results Available From Ongoing Phase I Trial Of Orally Administered Pd-L1 Inhibitor, Ccx559

Churchill Capital XI

06/06/2022 14:15

June 6 (Reuters) - ChemoCentryx Inc  CCXI.O :
    * CHEMOCENTRYX REPORTS SAFETY RESULTS AVAILABLE FROM ONGOING
PHASE
I TRIAL OF ORALLY ADMINISTERED PD-L1 INHIBITOR, CCX559, AT THE
2022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
    * CHEMOCENTRYX INC - CONSISTENT WITH APPROVED ANTIBODY
INHIBITORS
OF PD-L1, CCX559 DEMONSTRATES IMMUNOMODULATORY ACTIVITY IN FIRST
CYCLE OF TREATMENT
    * CHEMOCENTRYX INC - SAFETY AND TOLERABILITY ALLOW FOR
CONTINUED
DOSE ESCALATION WITH NO DOSE LIMITING TOXICITIES TO DATE

Source text for Eikon:  ID:nGNXbllK8P 
Further company coverage:  CCXI.O 

 ((reuters.briefs@thomsonreuters.com;))